Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 22 min ago
Peer-reviewedCC BY-NC-ND 4.0Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Nicotine-associated cardiovascular dysfunction: From pharmacological insights to emerging therapeutic interventions

  1. 1Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, United States

Abstract

Nicotine is a highly bioactive and addictive alkaloid that exerts prevalent cardiovascular and metabolic toxicity independent of other combustion-derived chemicals. Its rapid absorption and interaction with nicotinic acetylcholine receptors initiate a cascade of oxidative, inflammatory, and neuropharmacological responses that interrupt vascular, renal, and metabolic homeostasis. Nicotine triggers NADPH oxidase, mitochondrial dysfunction, and acid sphingomyelinase-ceramide signaling, resulting in reduced nitric oxide bioavailability, endothelial dysfunction, and lipid raft aggregation that promotes NLRP3 inflammasome activation. These mechanisms contribute to hypertension, atherosclerosis, arrhythmias, and heart failure through augmented oxidative stress, impaired vasodilation, sympathetic activation, and structural cardiac remodeling. Besides the cardiovascular system, nicotine disrupts lipid and glucose metabolism, induces podocyte injury, accelerates chronic kidney disease and promotes insulin resistance via inflammatory and redox-sensitive pathways. Understanding the molecular mechanisms driving nicotine toxicity is essential for developing targeted interventions. Emerging therapeutic strategies include pharmacotherapies for dependence, antihypertensive and lipid-lowering agents, metabolic modulators, antioxidants, and inhibitors of inflammasome or ceramide signaling. Overall, this review synthesizes current mechanistic and pharmacological evidence to clarify how nicotine contributes to cardiovascular and systemic disease and highlights the therapeutic opportunities to mitigate its increasing public health burden.

Related

  1. Metabolic dysfunction-associated steatotic liver disease: Pathogenesis, complications and pharmacological treatment
    Kyung-Soo Kim, Soo Lim, Cheol-Young Park
    EXCLI JournalPeer-reviewedCC BY 4.0Full textGeneral medicinePMC
  2. Risk assessment of cardiovascular disease-related mortality in metabolic dysfunction-associated steatotic liver disease
    Donghee Kim, Pojsakorn Danpanichkul, Do Han Kim +3
    Clinical and Molecular HepatologyPeer-reviewedCC BY-NC 3.0Full text1 citedGeneral medicinePMC
  3. Metabolic and Renal Dysfunction Are Associated With Intraplaque Lipid Burden Assessed by Near‐Infrared Spectroscopy Intravascular Ultrasound: Insights Into the Cardiovascular–Kidney–Metabolic Axis
    Hyungdon Kook, Woohyeun Kim, Seong Rae Cho +1
    Journal of the American Heart AssociationPeer-reviewedLicence not statedCardiovascular medicineCrossref
  4. Wnt/β‐catenin–mTOR crosstalk in TSC-associated epilepsy: pharmacological evidence and therapeutic opportunities
    Roaya S. Alqurashi
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyCrossref
  5. The CYB5R3–mARC1 Redox Axis in Metabolic Dysfunction-associated Steatotic Liver Disease: Mechanistic Basis and Therapeutic Prospects across the Steatosis–Cirrhosis–Hepatocellular Carcinoma Spectrum
    Journal of Clinical and Translational HepatologyPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
BibTeX
@article{rahman2026nicotineassociated,
  title = {{Nicotine-associated cardiovascular dysfunction: From pharmacological insights to emerging therapeutic interventions}},
  author = {Mohammad Atiqur Rahman and Md Areeful Haque and Saisudha Koka and Krishna M. Boini},
  journal = {Biomedicine \& pharmacotherapy = Biomedecine \& pharmacotherapie},
  year = {2026},
  month = jun,
  doi = {10.1016/j.biopha.2026.119610},
  url = {https://doi.org/10.1016/j.biopha.2026.119610},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Nicotine-associated cardiovascular dysfunction: From pharmacological insights to emerging therapeutic interventions
AU  - Mohammad Atiqur Rahman
AU  - Md Areeful Haque
AU  - Saisudha Koka
AU  - Krishna M. Boini
PY  - 2026
DA  - 2026/06/08
JO  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
DO  - 10.1016/j.biopha.2026.119610
UR  - https://doi.org/10.1016/j.biopha.2026.119610
AB  - Nicotine is a highly bioactive and addictive alkaloid that exerts prevalent cardiovascular and metabolic toxicity independent of other combustion-derived chemicals. Its rapid absorption and interaction with nicotinic acetylcholine receptors initiate a cascade of oxidative, inflammatory, and neuropharmacological responses that interrupt vascular, renal, and metabolic homeostasis. Nicotine triggers NADPH oxidase, mitochondrial dysfunction, and acid sphingomyelinase-ceramide signaling, resulting in reduced nitric oxide bioavailability, endothelial dysfunction, and lipid raft aggregation that promotes NLRP3 inflammasome activation. These mechanisms contribute to hypertension, atherosclerosis, arrhythmias, and heart failure through augmented oxidative stress, impaired vasodilation, sympathetic activation, and structural cardiac remodeling. Besides the cardiovascular system, nicotine disrupts lipid and glucose metabolism, induces podocyte injury, accelerates chronic kidney disease and promotes insulin resistance via inflammatory and redox-sensitive pathways. Understanding the molecular mechanisms driving nicotine toxicity is essential for developing targeted interventions. Emerging therapeutic strategies include pharmacotherapies for dependence, antihypertensive and lipid-lowering agents, metabolic modulators, antioxidants, and inhibitors of inflammasome or ceramide signaling. Overall, this review synthesizes current mechanistic and pharmacological evidence to clarify how nicotine contributes to cardiovascular and systemic disease and highlights the therapeutic opportunities to mitigate its increasing public health burden.
SN  - 0753-3322
SN  - 1950-6007
ER  -